Stichting can also be used to evade activist investors, and removing it has been one of the changes Mylan shareholders have been calling for, Chen noted. RELATED: GSK, Pfizer go for radical makeovers with giant consumer combo destined for spinoff Last August, amid shareholder criticism, Mylan initiated a strategic review that it said was "actively evaluating a wide range of alternatives." Just a month before that, Pfizer unveiled its own restructuring—which just took effect this year—that granted its established medicines business "substantial autonomy" within Pfizer.